3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
7
Phase 2/3
2
Phase 1/2
2
Phase NA
1
Phase 4
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Genitourinary
1
Conditions
Multiple Myeloma
1
Hodgkin Disease
1
Castrate Resistant Prostate Cancer
1
Interventions
Cisplatin
54
Cyclophosphamide
42
Fluorouracil
41
Oxaliplatin
36
Capecitabine
35
Docetaxel
34
Gemcitabine
32
Drug Therapy
32
Radiotherapy
31
Paclitaxel
25
Dexamethasone
23
Carboplatin
23
Leucovorin
21
Etoposide
17
Doxorubicin
17
Cytarabine
17
apatinib
16
Methotrexate
16
Magnetic Resonance Spectroscopy
14
Radiation
13
Epirubicin
13
Busulfan
13
Bevacizumab
13
Surgical Procedures, Operative
12
Neoadjuvant Therapy
12
Letrozole
12
Decitabine
12
Saline Solution
11
Irinotecan
11
venetoclax
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
OTHER
×
Lenograstim
×
Clear all
NCT01907009
2023-04-19
MEL-CAP
Barts & The London NHS Trust
Phase 2/3
Terminated
29 enrolled
NCT01085058
2010-03-11
CU01
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2/3
Completed
169 enrolled